The landscape of clinical mycology is constantly changing. New therapies for malignant and
autoimmune diseases have led to new risk factors for unusual mycoses. Invasive …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Immunomodulatory and immunosuppressive treatments for multiple sclerosis (MS) are
associated with an increased risk of infection, which makes treatment of this condition …

Multiple sclerosis (MS) is a common, disabling, putatively autoimmune neurological disease
with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a …

Abstract Sphingosine‐1‐phosphate (S1P) is a signalling lipid that regulates many cellular
processes in mammals. One well‐studied role of S1P signalling is to modulate T‐cell …

Key Points Cryptococcal Disease in Diverse Hosts Worldwide, cryptococcal meningitis kills
up to 180,000 persons annually and is the most common cause of nonviral meningitis in the …

Introduction: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative
disease with an unpredictable outcome. Immune-modulatory treatment aims at decreasing …

In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly.
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …

Background Fingolimod is a disease-modifying agent used in the treatment of
relapsing/remitting multiple sclerosis. In MS clinical studies, the overall rate of infections in …

Introduction: Fingolimod was the first oral and the first in class disease modifying treatment
in multiple sclerosis that acts as sphingosine-1-phospathe receptor agonist. Since approval …